[Acute traumatic haemorrhagic shock and transfusion: what's new in 2009?].
In spite of continuous progress in surgery and in interventional radiology, massive haemorrhage remains a leading cause of death in traumatology. The transfusional strategy appears a key step in the treatment of haemorrhagic shock. In the light of new insights into the pathophysiology of coagulopathies associated with traumatic shock it seems reasonable to transfuse patients with haemorrhagic shock earlier than previously recommended.
Morel
N
N
Pôle des urgences adultes, service de réanimation des urgences, hôpital Pellegrin, place Amélie-Raba-Léon, Bordeaux cedex, France. nicolas.morel@chu-bordeaux.fr
Morel
O
O
Chimot
L
L
Lortet
V
V
Julliac
B
B
Lelias
A
A
Merson
L
L
Dabadie
Ph
P
D000138:Acidosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000208:Acute Disease; D000941:Antigens / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D001803:Blood Transfusion / Q000379:methods* / Q000639:trends; D001810:Blood Volume; D003131:Combined Modality Therapy; D004632:Emergency Medical Services / Q000379:methods*; D005167:Factor VII / Q000627:therapeutic use; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007035:Hypothermia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000860:Hypoxia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012771:Shock, Hemorrhagic / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D014947:Wounds and Injuries / Q000150:complications*
D000941:Antigens; D011994:Recombinant Proteins; C042580:factor VII clotting antigen; D005167:Factor VII